RxDoctor Payments Data

Ian Cook, MD

Obstetrics & Gynecology · Charlottesville, VANPI 1154703031

Payments from drug & device makers

$1,496in general payments, 2019–2025

Across 31 payments — averaging $48.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$221
  • Abbott$211
  • Intuitive Surgical$208
  • Merck$177
  • Johnson & Johnson$145
  • AstraZeneca$128
  • plus $406 from 6 others

What the payments were for

  • Food & beverage$1,47899%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Olympus America Inc.2$221
Abbott3$211
Intuitive Surgical2$208
Merck10$177
Johnson & Johnson1$145
AstraZeneca2$128
AbbVie2$122
Eisai Inc.5$117
Immunogen, Inc.1$80
Medtronic1$55
GSK1$21
On Target Laboratories, Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,496 in reported general payments places this provider in the 70th percentile of 992 obstetrics & gynecology providers in Virginia.

See all obstetrics & gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$80,762
Medicare patients
122
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib22$229,720
EliquisApixaban14$10,448
Megestrol Acetate24$1,058
Prochlorperazine Maleate26$321
Lidocaine-PrilocaineLidocaine/Prilocaine19$276
Dexamethasone34$257
Ondansetron Hcl28$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$128$229,72022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 992 obstetrics & gynecology providers in Virginia.

Other obstetrics & gynecology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →